Viking Global Investors LP Editas Medicine, Inc. Transaction History

Viking Global Investors LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$28.06 - $37.16 $11.6 Million - $15.3 Million	-413,000 Closed	0 $0
Q2 2020 Aug 07, 2020	SELL	$18.5 - $34.34 $1.83 Million - $3.41 Million	-99,179 Reduced 19.36%	413,000 $12.2 Million
Q1 2020 May 13, 2020	SELL	$14.88 - $32.78 $3.29 Million - $7.25 Million	-221,222 Reduced 30.16%	512,179 $10.2 Million
Q3 2019 Nov 13, 2019	SELL	$22.49 - $26.81 $4.45 Million - $5.31 Million	-198,000 Reduced 21.26%	733,401 $16.7 Million
Q2 2018 Aug 14, 2018	SELL	$31.4 - $41.01 $3.26 Million - $4.26 Million	-103,903 Reduced 10.04%	931,401 $33.4 Million
Q1 2018 May 15, 2018	SELL	$29.84 - $44.08 $20.1 Million - $29.7 Million	-674,097 Reduced 39.43%	1,035,304 $34.3 Million
Q2 2016 Aug 15, 2016	SELL	N/A	-426,122 Reduced 19.95%	1,709,401 $41.7 Million
Q1 2016 May 16, 2016	BUY	N/A	2,135,523	2,135,523 $73.8 Million

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $104M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Viking Global Investors LP, based on Form 13F filings with the SEC.

Stay updated on Viking Global Investors LP with notifications on news.